Subanalysis of the APHINITY trial
Dr Elisa Agostinetto, a medical oncologist and research fellow at the Institut Jules Bordet in Brussels, presented during a Poster Spotlight Session at SABCS 2023 a sub-analysis of the APHINITY-trial. The analysis aimed to assess the benefit of adding pertuzumab to trastuzumab and chemotherapy in early HER2+ breast cancer based on estrogen receptor (ER) and HER2 expression.
The APHINITY trial, a randomized phase three study, examined the addition of pertuzumab to trastuzumab and chemotherapy in early HER2-positive breast cancer patients. The analysis categorized HER2 expression as low or high and ER expression as positive or negative, with centrally assessed cutoffs.
The analysis included 4782 patients with a median follow-up of 74 months. The key finding was a consistent invasive disease-free survival benefit from adding pertuzumab across all patient subgroups based on ER and HER2 expression. The forest plot displayed differences in hazard ratios among subgroups, but the interpretation was speculative due to wide confidence intervals and some crossing the unit boundary. The conclusion emphasized that all patients treated with pertuzumab derived the same benefit, regardless of their ER or HER2 expression. The exploratory nature of the findings suggested they should not guide clinical treatment decisions at this point.
Reference:
Agostinetto E.. et al., The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a sub-analysis of the APHINITY trial – SABCS 2023, #PS09-04
With the educational support of:
 |
 |
 |